Printer Friendly

White Blood Cell and Granulocyte Counts Are Independent Predictive Factors for Prognosis of Advanced Pancreatic Caner.

1. Introduction

Pancreatic cancer is one of the most fatal cancers. It is ranked the fourth leading cause of cancer deaths in the United States for both sexes [1]. In China, the incidence of pancreatic cancer was noted to be 90,100 with a mortality rate of about 79,400 per year in 2015 [2]. Pancreatic cancer cases are usually diagnosed only in an advanced stage. Also, it is associated with limited available effective treatment options. For these reasons, the 5-year survival rate of pancreatic cancer is below 5%. For patients suffering from advanced pancreatic cancer, the Karnofsky performance status (KPS) usually gets worsened, so effective treatment and precise selection of patients are of great importance. Currently, feasible prognosis prediction methods are still lacking for this ailment. Although pathological classification could be used as a good predictor, it is not easy to harvest the tumor tissue for biopsy in most of the patients.

However, certain recent blood test results provide us with clues for cancer prognosis prediction. These results include white blood cell counts, neutrophil counts, lymphocyte counts, granulocyte counts, neutrophil-to-lymphocyte ratios (NLRs), and platelet to lymphocyte ratios (PLRs). These parameters reflect the inflammatory status of the patient, which may play decisive roles at different stages as the tumor progresses. The stages include initiation, promotion, invasion, and metastasis [3, 4]. Both innate (including macrophages, neutrophils, mast cells, myeloid-derived suppressor cells, dendritic cells, and natural killer cells) and adaptive (T and B lymphocytes) immune cells exist in the tumor's microenvironment. These immune cells participate in inflammatory responses within the microenvironment of the tumor. The consequences of inflammation in cancer are still under debate. On the one hand, inflammation may promote tumor progression [5]. On the other hand, it enhances tumor antigen cross-presentation and subsequently induces antitumor immune responses [6].

Neutrophil is the most common and vital element of inflammation that plays a significant role influencing the microenvironment of the tumor [7]. NLR is a general inflammatory indicator that can be estimated by dividing the neutrophil count by the lymphocyte count. NLR has been proposed as a predictive factor for different types of carcinomas, such as metastatic melanoma [8], esophageal cancer [9], colorectal cancer [10], non-small-cell lung cancer (NSCLC) [11], metastatic castration-resistant prostate cancer (mCRPC) [12], diffuse large B-cell lymphoma (DLBCL) [13], and pancreatic cancer [14]. PLR is another systemic inflammation index that can be calculated by dividing the circulating platelet count by the lymphocyte count. PLR has been shown to take on prognostic roles in several cancers, for example, breast cancer [15], NSCLC [16], and nasopharyngeal cancer [17]. However, the predictive roles of these factors in pancreatic cancer patients are still controversial.

The prognostic role of the inflammatory factors in patients with pancreatic cancer are evaluated in the present study, which aims at coming up with clues facilitating the prognosis of pancreatic cancer by using results from routine laboratory tests.

2. Materials and Methods

2.1. Patients. Patients with pancreatic cancer who had visited our department at Fudan University Shanghai Cancer Center (FUSCC) between January 2012 and January 2014 were included in this retrospective study. Diagnoses of pancreatic cancer for patients who had received surgery before but had experienced a recurrence or metastasis were performed through pathological examinations of the respective surgical samples. For patients who could not tolerate surgical treatment in their first visit to doctors, the diagnosis was confirmed by pathological biopsy. The study was approved by the ethics committee of FUSCC. Informed consent was acquired from each patient. All relevant blood tests were performed in accordance with institutional guidelines and regulations. Patient characteristics were extracted from their medical records. The characteristics included sex, age, location of the pancreas cancer, the TNM stage, outcomes, and the blood test--white blood cell (WBC), granulocyte, neutrophil, lymphocyte, and platelet--results at the time of diagnosis. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values were calculated. The primary endpoint was overall survival (OS) as calculated from the date of first diagnosis to death or the last follow-up. Patients with no data, no pathological diagnoses, no informed consent, or poor treatment compliance were excluded. Patients were followed up every six months until death or loss of follow-up.

2.2. Statistical Analysis. All quantitative data were presented as SEM or median (range) as specified. The quantitative data were separated using median values and analyzed using Prism GraphPad (version 5, La Jolla, CA) and SPSS software (version 19.0, Armonk, NY). The Kaplan-Meier method was applied while conducting univariate analyses. Obvious differences between groups were determined using log-rank tests. The Cox proportional hazard model was used for multivariate analysis. Hazard ratios (HRs) were reported as relative risks along with the 95% confidence intervals (CIs). All tests were 2-sided, and p < 0.05 was taken as the criterion indicating statistical significance.

3. Results

214 patients who were pathologically diagnosed with pancreatic cancer were included. The records of these patients were retrieved and analyzed. The median age of all patients was 61 (age range: 27-85). 36.0% of them were female (77/214). Almost 38.8% (83/214) of patients were categorized as TNM stage 3, and 61.2% (131/214) of patients were at TNM stage 4 (Table 1). The WBC count was (6.4 [+ or -] 0.2) x [10.sup.9]/L, median value 5.8 (range: 1.7-20.3) x [10.sup.9]/L; granulocyte count (4.3 [+ or -] 0.1) x [10.sup.9]/L, median value 3.7 (range: 0.7-18.3) x [10.sup.9]/L; neutrophil count (4.2 [+ or -] 0.2) x [10.sup.9]/L, median value 3.9 (range: 0.9-17.9) x [10.sup.9]/L; lymphocyte count (1.5 [+ or -] 0.0) x [10.sup.9]/L, median value 1.4 (range: 0.3-4.2 x [10.sup.9]/L); and platelet count (180.1 [+ or -] 5.1) x [10.sup.9]/L, median value 170 (range: 27-543) x [10.sup.9]/L. The NLR was 3.5 [+ or -] 0.2, with a median value of 2.8 (range: 0.6-22.8). The PLR value was 135.9 [+ or -] 4.9, with a median value of 124.6 (range: 30-604). Please see Table 2 for full details.

The prognostic roles of blood test parameters were investigated using univariable and multivariable analyses. The univariable analyses indicated that patients with baseline NLR [greater than or equal to] 2.8 (P < 0.0001), WBC [greater than or equal to] 5.8 x [10.sup.9]/L (P < 0.0001), granulocyte [greater than or equal to] 3.7 x [10.sup.9]/L (P < 0.0001), neutrophil [greater than or equal to] 3.9 x [10.sup.9]/L (P < 0.0001), lymphocyte < 1.4x [10.sup.9]/L (p = 0.034) had poor OS figures for this study cohort. However, age, gender, location of carcinoma, TNM classification, and PLR were not significantly associated with the prognosis (Table 3 and Figure 1).

In multivariate analysis, the Cox proportional hazard model was performed. The analysis revealed that WBC [greater than or equal to] 5.8 x [10.sup.9]/L (HR = 1.808; 95% CI 1.055-3.096; p = 0.031) and granulocyte [greater than or equal to] 3.7x [10.sup.9]/L (HR = 7.346; 95% CI 1.275-42.321; P = 0.026) were independent prognostic factors for OS in pancreatic cancer patients. However, age, gender, location of carcinoma, TNM classification, neutrophil, lymphocyte, NLR, and PLR were not independent factors for the prognosis of pancreatic cancer (Table 4).

4. Discussion

In view of low survival rates and disappointing therapeutic options for pancreatic cancer, many researchers have searched for applicable prognostic factors and clinical indices that are significantly related to pancreatic cancer survival. It has been reported that inflammation and nutritious status are closely related to certain malignant tumors. Monitoring of inflammation status can be easily achieved at a clinic using laboratory testing for WBCs, neutrophils, granulocytes, and so on Therefore, in the present study, we tried to get some clues from routine blood test results for the prognosis of pancreatic cancer.

In our study cohort, the baseline values of WBC, granulocyte, neutrophil, lymphocyte, and NRL were associated with the overall survival of pancreatic cancer patients. However, our multivariate analyses indicated that only the baseline values of WBC and granulocyte count could be used as independent predictive factors for pancreatic cancer. High values of WBC and granulocyte test may indicate poor survival. Likewise, it has been reported that the leukocyte, NLR, and other indicators may reflect systemic inflammation [18-20]. Neutrophils can promote angiogenesis and repress the immune system from supporting tumor growth [3, 21]. The vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP), important cytokines and chemokines for tumor microenvironment angiogenesis and metastasis, are believed to be secreted by neutrophils [22,23]. It has been suggested that increased neutrophil counts are associated with greater tumor sizes and poorer survival rates in patients with confined nasopharyngeal cancer [24] and renal cell carcinoma [25]. Since neutrophils constitute the majority population of granulocytes, which is a main component of WBC, it is reasonable to expect that the increase of WBC in this study was mainly due to the increase of granulocytes, which in turn was a consequence of an increase in neutrophil count.

In the present study, lymphocyte count was negatively associated with survival rate. Reduced lymphocyte counts predict poor survival rates. These results are consistent with other observations [26]. It is widely accepted that lymphocytes play an important role in determining immune responses against tumor. High lymphocyte values result in cytotoxic cell death and inhibit tumor cell proliferation and migration [21, 27]. In patients with carcinoma, the programmed death 1 or programmed death 1 ligand (PD-1/ PD-L1) signaling the microenvironment of tumor may compromise the cytotoxic capability of T lymphocytes. In pancreatic cancer patients, high PD-1 expression level on [CD8.sup.+] T lymphocytes is associated with the poor overall survival rate as well as the disease-free survival rate [28]. In patients with pancreatic ductal adenocarcinoma (PDA), PD-L1 negative and HLA class 1 high expression may predict a better prognosis [29]. The activation of PD-1/PD-L1 pathways inhibits the infiltration of cytotoxic T lymphocytes into tumor tissue to kill cancerous cells. This inability of lymphocytes contributes to the survival and progression of tumor cells [30]. Meanwhile, the neutrophil may also suppress the cytotoxic activity of lymphocytes [31]. Our study has shown that decreased lymphocytes are correlated with poor prognosis, a finding that is a consistent observation in previous studies.

In our study, the TNM classification was not associated with the prognosis of the disease. This is different from others' observations [32, 33]. This is probably due to the extremely long survival times of three stage 4 patients, which were 1369, 2226, and 2427 days, respectively.

This study has some limitations. First of all, it was a single-center study with a relatively small sample size. Further, the subjects were all Chinese. This may have limited the generalizability of its findings. Second, due to concealed manifestations, the vast majority of patients are diagnosed at an advanced stage. Therefore, we did not enroll the early-stage patients in view of the very small sample size they would constitute. In addition, our study was retrospective and the exposure data were collected prior to the initiation of the study. Therefore, C-reactive protein (CRP) was not evaluated by us although it is an objective inflammation marker and has been found to be a prognostic indicator in diffuse large B-cell lymphoma [34, 35]. A multicenter prospective study with a larger sample size is advisable in the future for improving the generalizability of our findings.

5. Conclusion

Pretreatment WBC and granulocyte alone could be used as an independent factor for pancreatic cancer prognosis. The existence of inflammation in pancreatic cancer may indicate poor survival. Our study has pointed to a feasible way for the prognosis of pancreatic cancer from routine and simple laboratory test results.

https://doi.org/10.1155/2018/8096234

Data Availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interests in this study.

Authors' Contributions

Lanyun Feng and Shihui Gu contributed equally to this study.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (General Program no. 81373894), National Science Fund for Young Scholars (nos. 81102004 and 81100934), and Shanghai Health Bureau Chinese Medicine Supporting Fund (no. 2010QJ032A).

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2016," CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7-30, 2016.

[2] W. Chen, R. Zheng, P. D. Baade et al., "Cancer statistics in China, 2015," CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115-132, 2016.

[3] S. I. Grivennikov, F. R. Greten, and M. Karin, "Immunity, inflammation, and cancer," Cell, vol. 140, no. 6, pp. 883-899, 2010.

[4] C. I. Diakos, K. A. Charles, D. C. McMillan, and S. J. Clarke, "Cancer-related inflammation and treatment effectiveness," The Lancet Oncology, vol. 15, no. 11, pp. e493-e503, 2014.

[5] M. Ammirante, J.-L. Luo, S. Grivennikov, S. Nedospasov, and M. Karin, "B-cell-derived lymphotoxin promotes castration-resistant prostate cancer," Nature, vol. 464, no. 7286, pp. 302-305, 2010.

[6] L. Zitvogel, L. Apetoh, F. Ghiringhelli, and G. Kroemer, "Immunological aspects of cancer chemotherapy," Nature Reviews Immunology, vol. 8, no. 1, pp. 59-73, 2008.

[7] C. A. Dumitru, S. Lang, and S. Brandau, "Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression," Seminars in Cancer Biology, vol. 23, no. 3, pp. 141-148, 2013.

[8] F. C. M. Cananzi, A. Dalgleish, and S. Mudan, "Surgical management of intraabdominal metastases from melanoma: role of the neutrophil to lymphocyte ratio as a potential prognostic factor," World Journal of Surgery, vol. 38, no. 6, pp. 1542-1550, 2014.

[9] E. J. Yoo, J. C. Park, E. H. Kim et al., "Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer," Digestive and Liver Disease, vol. 46, no. 9, pp. 846-853, 2014.

[10] B. Azab, F. Mohammad, N. Shah et al., "The value of the pretreatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer," Cancer Biomarkers, vol. 14, no. 5, pp. 303-312, 2014.

[11] H. Zhang, H. Xia, L. Zhang, B. Zhang, D. Yue, and C. Wang, "Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer," The American Journal of Surgery, vol. 210, no. 3, pp. 526-535, 2015.

[12] A. J. Templeton, C. Pezaro, A. Omlin et al., "Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio," Cancer, vol. 120, no. 21, pp. 3346-3352, 2014.

[13] K. Troppan, A. Deutsch, A. Gerger et al., "The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma," British Journal of Cancer, vol. 110, no. 2, pp. 369-374, 2014.

[14] J. J. Yang, Z. G. Hu, W. X. Shi, T. Deng, S. Q. He, and S. G. Yuan, "Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis," World Journal of Gastroenterology, vol. 21, no. 9, pp. 2807-2815, 2015.

[15] C. H. Koh, N. Bhoo-Pathy, K. L. Ng et al., "Utility of pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer," British Journal of Cancer, vol. 113, no. 1, pp. 150-158, 2015.

[16] Q. T. Zhao, Z. Yuan, H. Zhang et al., "Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients," International Journal of Cancer, vol. 139, no. 1, pp. 164-170, 2016.

[17] R. Jiang, X. Zou, W. Hu et al., "The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients," Tumor Biology, vol. 36, no. 10, pp. 7775-7787, 2015.

[18] Z. Mei, L. Shi, B. Wang et al., "Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies," Cancer Treatment Reviews, vol. 58, pp. 1-13, 2017.

[19] A. P. van Rossum, L. T. Vlasveld, I. N. Vlasveld et al., "Granulocytosis and thrombocytosis in renal cell carcinoma: a pro-inflammatory cytokine response originating in the tumour," The Netherlands Journal of Medicine, vol. 67, no. 5, pp. 191-194, 2009.

[20] M. J. Proctor, P. G. Horgan, D. Talwar, C. D. Fletcher, D. S. Morrison, and D. C. McMillan, "Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study," Cancer, vol. 119, no. 12, pp. 2325-2332, 2013.

[21] L. M. Coussens and Z. Werb, "Inflammation and cancer," Nature, vol. 420, no. 6917, pp. 860-867, 2002.

[22] D. Bausch, T. Pausch, T. Krauss et al., "Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma," Angiogenesis, vol. 14, no. 3, pp. 235-243, 2011.

[23] E. M. Bekes, B. Schweighofer, T. A. Kupriyanova et al., "Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation," The American Journal of Pathology, vol. 179, no. 3, pp. 1455-1470, 2011.

[24] J.-R. He, G.-P. Shen, Z.-F. Ren et al., "Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma," Head & Neck, vol. 34, no. 12, pp. 1769-1776, 2012.

[25] H. K. Jensen, F. Donskov, N. Marcussen, M. Nordsmark, F. Lundbeck, and H. von der Maase, "Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma," Journal of Clinical Oncology, vol. 27, no. 28, pp. 4709-4717, 2009.

[26] P. Fogar, C. Sperti, D. Basso et al., "Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome," Pancreas, vol. 32, no. 1, pp. 22-28, 2006.

[27] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancer-related inflammation," Nature, vol. 454, no. 7203, pp. 436-444, 2008.

[28] T. Shen, L. Zhou, H. Shen et al., "Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer," Scientific Reports, vol. 7, no. 1, p. 7848, 2017.

[29] D. Imai, T. Yoshizumi, S. Okano et al., "The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer," Cancer Medicine, vol. 6, no. 7, pp. 1614-1626, 2017.

[30] M. Feng, G. Xiong, Z. Cao et al., "PD-1/PD-L1 and immunotherapy for pancreatic cancer," Cancer Letters, vol. 407, pp. 57-65, 2017.

[31] H. Y. Shau and A. Kim, "Suppression of lymphokine-activated killer induction by neutrophils," The Journal of Immunology, vol. 141, no. 12, pp. 4395-4402, 1988.

[32] L. Huang, L. Jansen, Y. Balavarca et al., "Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations," Gut, 2017.

[33] G. Wiltberger, F. Krenzien, C. Benzing et al., "Prognostic accuracy of the seventh edition of the TNM classification compared with the fifth and sixth edition for distal cholangiocarcinoma," Annals of Surgical Oncology, vol. 23, no. 4, pp. 1320-1326, 2016.

[34] H. J. A. Adams, J. M. H. de Klerk, R. Fijnheer et al., "Prognostic value of anemia and C-reactive protein levels in diffuse large Bcell lymphoma," Clinical Lymphoma, Myeloma & Leukemia, vol. 15, no. 11, pp. 671-679, 2015.

[35] K. T. Troppan, K. Schlick, A. Deutsch et al., "C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients," British Journal of Cancer, vol. 111, no. 1, pp. 55-60, 2014.

Lanyun Feng, (1, 2) Shihui Gu, (3, 4, 5) Peng Wang, (1, 2) Hao Chen, (1, 2) Zhen Chen, (1, 2) Zhiqiang Meng, (1, 2) and Luming Liu (1, 2)

(1) Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

(2) Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

(3) Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, China

(4) Key Laboratory of Hand Reconstruction, Ministry of Health, Shanghai, China

(5) Shanghai Key Laboratory of Peripheral Nerve and Microsurgery, Shanghai, China

Correspondence should be addressed to Zhiqiang Meng; mengzhq@yeah.net and Luming Liu; llm1010@163.com

Received 21 January 2018; Revised 21 April 2018; Accepted 26 April 2018; Published 8 May 2018

Academic Editor: Amosy M'Koma

Caption: Figure 1: Kaplan-Meier survival curves for overall survival (OS) in patients with pancreatic cancer after diagnoses. (a) The OS of NLR < 2.8 was longer than that of NLR [greater than or equal to] 2.8 (p < 0.0001, log- rank). (b) The OS of patients with PLR < 124.6 was not significantly different from those with PLR > 124.6 (p = 0.182, log-rank). (c) The OS of patients with baseline WBC < 5.8 x [10.sup.9]/L was longer than in those with WBC [greater than or equal to] 5.8 x [10.sup.9]/L (p < 0.0001, log-rank). (d) The OS of patients with baseline granulocyte < 3.7 x [10.sup.9]/L was longer than in those with granulocyte [greater than or equal to] 3.7 x [10.sup.9]/L (p < 0.0001, log-rank). (e) The OS of patients with baseline neutrophil < 3.9 x [10.sup.9]/L was longer than in those with neutrophil [greater than or equal to] 3.9 x [10.sup.9]/L (p < 0.0001, log-rank). (f) The OS of patients with baseline lymphocyte < 1.4x [10.sup.9]/L was longer than in those with WBC [greater than or equal to] 1.4x [10.sup.9]/L (p = 0.034, log-rank).
Table 1: Basic characteristics of 214 pancreatic
cancer patients.

Characteristics                 N (%) (n = 214)

Gender
  Female                          77 (36.0%)
  Male                            137 (64.0%)
Age
  [less than or equal to] 60      101 (47.2%)

  >60                             113 (52.8%)
Location
  Head                            81 (37.9%)
  Body/tail                       133 (62.1%)
TNM classification
  Stage 3                         83 (38.8%)
  Stage 4                         131 (61.2%)

Table 2: Baseline blood test results of the 214
pancreatic patients included.

Category                         Mean (SD)    Median (range)

WBC (x [10.sup.9]/L)             6.4 (0.2)    5.8 (1.7-20.3)
Granulocyte (x [10.sup.9]/L)     4.3 (0.1)    3.7 (0.7-18.3)
Neutrophil (x [10.sup.9]/L)      4.2 (0.2)    3.9 (0.9-17.9)
Lymphocyte (x [10.sup.9]/L)      1.5 (0.0)    1.4 (0.3-4.2)
Platelet (x [10.sup.9]/L)       180.1 (5.1)    170 (27-543)
NLR                              3.5 (0.2)    2.8 (0.6-22.8)
PLR                             135.9 (4.9)   124.6 (30-604)

Table 3: Univariate analyses examining the association between
clinical characteristics and survival in pancreatic cancer patients.

Characteristics                                      N (%)       HR

Gender
  Female                                          77 (36.0%)      1
  Male                                            137 (64.0%)   1.121
Age
  [less than or equal to] 60                      101 (47.2%)     1
  >60                                             113 (52.8%)   0.950
Locations
  Head                                            81 (37.9%)      1
  Body/tail                                       133 (62.1%)   1.352
TNM classification
  Stage 3                                         83 (38.8%)      1
  Stage 4                                         131 (61.2%)   0.892
Baseline WBC
  <5.8 x [10.sup.9]/L                              107 (50%)      1
  [greater than or equal to] 5.8 x [10.sup.9]/L    107 (50%)    2.132
Baseline granulocyte
  <3.7 x [10.sup.9]/L                             106 (49.5%)     1
  [greater than or equal to] 3.7 x [10.sup.9]/L   108 (50.5%)   2.849
Baseline neutrophil
  <3.9 x [10.sup.9]/L                             104 (48.6%)     1
  [greater than or equal to] 3.9 x [10.sup.9]/L   110 (51.4%)   2.488
Baseline lymphocyte
  <1.4 x [10.sup.9]/L                             123 (57.5%)     1
  [greater than or equal to] 1.4 x [10.sup.9]/L   91 (42.5%)    0.710
Baseline NLR
  <2.8                                            105 (49.1%)     1
  [greater than or equal to] 2.8                  109 (50.9%)   2.183
Baseline PLR
  <124.6                                           107 (50%)      1
  [greater than or equal to] 124.6                 107 (50%)    1.241

Characteristics                                     95% CI      p value

Gender
  Female                                           Reference
  Male                                            0.800-1.570    0.508
Age
  [less than or equal to] 60                       Reference
  >60                                             0.691-1.305    0.750
Locations
  Head                                             Reference
  Body/tail                                       0.965-1.893    0.080
TNM classification
  Stage 3                                          Reference
  Stage 4                                         0.314-1.755    0.494
Baseline WBC
  <5.8 x [10.sup.9]/L                              Reference
  [greater than or equal to] 5.8 x [10.sup.9]/L   1.524-2.976   <0.0001
Baseline granulocyte
  <3.7 x [10.sup.9]/L                              Reference
  [greater than or equal to] 3.7 x [10.sup.9]/L   2.016-4.016   <0.0001
Baseline neutrophil
  <3.9 x [10.sup.9]/L                              Reference
  [greater than or equal to] 3.9 x [10.sup.9]/L   1.770-3.497   <0.0001
Baseline lymphocyte
  <1.4 x [10.sup.9]/L                              Reference
  [greater than or equal to] 1.4 x [10.sup.9]/L   0.516-0.974    0.034
Baseline NLR
  <2.8                                             Reference
  [greater than or equal to] 2.8                  1.567-3.040   <0.0001
Baseline PLR
  <124.6                                           Reference
  [greater than or equal to] 124.6                0.904-1.704    0.182

HR: hazard ratio; CI: confidence interval; WBC: white blood cell; NLR:
neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.

Table 4: Multivariate analyses examining the association between
clinical characteristics and survival in pancreatic cancer patients.

Characteristics                            N (%)       HR

Gender
  Female                                77 (36.0%)      1
  Male                                  137 (64.0%)   1.277
Age
  [less than or equal to] 60            101 (47.2%)     1
  >60                                   113 (52.8%)   0.763
Locations
  Head                                  81 (37.9%)      1
  Body/tail                             133 (62.1%)   1.384
TNM classification
  Stage 3                               83 (38.8%)      1
  Stage 4                               131 (61.2%)   0.888
Baseline WBC
  <5.8 x [10.sup.9]/L                   107 (50%)      1
  [greater than or equal to] 5.8 x      107 (50%)    1.808
    [10.sup.9]/L
Baseline granulocyte
  <3.7 x [10.sup.9]/L                   106 (49.5%)     1
  [greater than or equal to] 3.7 x      108 (50.5%)   7.346
    [10.sup.9]/L
Baseline neutrophil
  <3.9 x [10.sup.9]/L                   104 (48.6%)     1
  [greater than or equal to] 3.9 x      110 (51.4%)   4.682
    [10.sup.9]/L
Baseline lymphocyte
  <1.4 x [10.sup.9]/L                   123 (57.5%)     1
  [greater than or equal to] 1.4 x      91 (42.5%)    0.678
    [10.sup.9]/L
Baseline NLR
  <2.8                                  105 (49.1%)     1
  [greater than or equal to] 2.8        109 (50.9%)   1.435
Baseline PLR
  <124.6                                107 (50%)       1
  [greater than or equal to] 124.6      107 (50%)     1.078

Characteristics                            95% CI      p value

Gender
  Female                                 Reference
  Male                                  0.896-1.821     0.177
Age
  [less than or equal to] 60             Reference
  >60                                   0.549-1.062     0.109
Locations
  Head                                   Reference
  Body/tail                             0.980-1.954     0.065
TNM classification
  Stage 3                                Reference
  Stage 4                               0.622-1.267     0.512
Baseline WBC
  <5.8 x [10.sup.9]/L                    Reference
  [greater than or equal to] 5.8 x      1.055-3.096     0.031
    [10.sup.9]/L
Baseline granulocyte
  <3.7 x [10.sup.9]/L                    Reference
  [greater than or equal to] 3.7 x      1.275-42.321    0.026
    [10.sup.9]/L
Baseline neutrophil
  <3.9 x [10.sup.9]/L                    Reference
  [greater than or equal to] 3.9 x      0.772-28.394    0.093
    [10.sup.9]/L
Baseline lymphocyte
  <1.4 x [10.sup.9]/L                    Reference
  [greater than or equal to] 1.4 x      0.444-1.037     0.073
    [10.sup.9]/L
Baseline NLR
  <2.8                                   Reference
  [greater than or equal to] 2.8        0.913-2.257     0.117
Baseline PLR
  <124.6                                 Reference
  [greater than or equal to] 124.6      0.752-1.546     0.683

Note: the multivariate Cox regression model adjusted for gender, age,
location, TNM classification, WBC, granulocyte, neutrophil, lymphocyte,
NLR, and PLR. HR: hazard ratio; CI: confidence interval; WBC: white
blood cell; NLR: neutrophil-to-lymphocyte ratio; PLR:
platelet-to-lymphocyte ratio.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Feng, Lanyun; Gu, Shihui; Wang, Peng; Chen, Hao; Chen, Zhen; Meng, Zhiqiang; Liu, Luming
Publication:Gastroenterology Research and Practice
Date:Jan 1, 2018
Words:4648
Previous Article:Changes in Hepatic Blood Flow and Liver Function during Closed Abdominal Hyperthermic Intraperitoneal Chemotherapy following Cytoreduction Surgery.
Next Article:The Development of Endoscopic Techniques for Treatment of Walled-Off Pancreatic Necrosis: A Single-Center Experience.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |